Skip to NavigationSkip to content

News

AstraZeneca has unveiled a double dose of approvals awarded to its medicines in Japan: Fasenra in asthma, and Lynparzain ovarian cancer.
Rumours of a $7billion Juno Therapeutics takeover by Celgene, accelerated approval in the US and Europe for Novartis' CAR T therapy Kymriah, and...
Novartis’ Sandoz unit had already staked a claim to being one of the leaders in the developing biosimilar market and has made another move to further...
UK regulator NICE has announced its decision not to recommend Pfizer’s Xalkori (crizotinib) for use on the NHS in the treatment of ROS1-positive...
Kite’s recent team up with Pfizer looks set to test whether its CAR-T treatment, Yescarto, can be boosted by the latter's monoclonal antibody for the...
AstraZeneca and X-Chem are to expand their existing drug discovery collaboration to focus on the synthesis and delivery of custom libraries, as well...
NICE rejected Janssen’s Darzalex (Daratumumab) back in March last year, concluding that it wasn’t able to accurately determine the efficacy of the...
Evidence is mounting against the efficacy of the common morning sickness pill Diclegis, as new study data reveals that it may not actually aid the...
The standard method of screening for the BRCA gene mutation is to invite women with a family history of either cancer for testing, researchers now...
Ipsen and Exelixis, partners in developing Cabometyx (cabozantinib), have revealed that they have cut short a Phase 3 trial into the benefit of the...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches